Defining the sites of interaction for corrector molecules on wildtype- and F508del-mutant cystic fibrosis transmembrane conductance regulator protein

定义野生型和 F508del 突变体囊性纤维化跨膜电导调节蛋白上校正分子的相互作用位点

• 批准号: 486619
• 负责人: Auw-Yang Kevin T
• 金额: $ 1.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-12-01 至 2023-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486619&lang=en
• 关键词: Biological Membrane; Cftr; Channel Function Assays; Corrector Compounds; Cystic Fibrosis; F508del; Photoactivatable Probes; Rare Mutations; Site Of Drug Interaction

Cystic fibrosis (CF) is a genetic disease that primarily impacts the lungs, leading to increased risks of airway infection and inflammation. Those with CF bear a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) protein (acts as a

囊性纤维化（CF）是一种遗传性疾病，主要影响肺部，导致气道感染和炎症的风险增加。那些患有CF的人在囊性纤维化跨膜传导调节因子（CFTR）蛋白中携带突变（作为一种免疫调节因子）。